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with constipation and 1:1 matched controls without constipa-
tion. Two- part semi-logarithmic multivariate regression models
were estimated to assess the impact of constipation on all-cause
resource utilization and costs. Smearing estimates were applied
to interpret results of the semi-logarithmic models. RESULTS:
We identiﬁed 39,485 patients of whom 2,519 (6.4%) had con-
stipation. Most patients with constipation were female (66%)
and 45 years old (68%). Compared to controls, the constipa-
tion group had higher rates of concurrent use of 2 opioids
(36% vs 24%; p < 0.001), discontinuation (31% vs 25%;
p < 0.001), and switching (45% vs 28%; p < 0.001) between
opioids. Patients with constipation were more likely to have
inpatient admission (odds ratio [OR] = 2.13; p < 0.001), emer-
gency (OR = 2.25; p < 0.001), outpatient visits (OR = 9.45;
p < 0.001), skilled nursing (OR = 2.26; p < 0.001), hospice
(OR = 2.27; p < 0.001) and home health services (OR = 1.54;
p < 0.001). Patients with constipation had signiﬁcantly higher
all-cause costs for emergency ($1,277 vs. $588), outpatient
($3,635 vs $1,861), nursing facility ($1,885 vs. $613), home
health ($1,909 vs. $1,069) and prescription drug ($12,005 vs
$6,809) services compared to patients without constipation.
CONCLUSION: Presence of constipation in opioid-treated
patients was found to have signiﬁcant impact on opioid use
patterns, health care utilization, and associated costs.
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OBJECTIVES: To estimate the economic burden of Digital
Ulcers (DU) in patients affected by Systemic Sclerosis (SSc, scle-
roderma), in the perspective of the NHS, patients, and society.
METHODS: Pilot, observational study based on a retrospective,
one-year, data collection of clinical characteristics and consump-
tion of resources in the target population, at the Rheumatology
Unit of the University Hospital in Padova. EC approval and
informed consent were obtained. Clinical records of adults with
limited/diffuse SSc, who developed >1 new DU (from September
2005 to April 2006) were analysed. Direct cost and indirect cost
per patient/year were calculated using 2007 published tariffs and
market values. RESULTS: Twenty patients (90% females) (age
51 +/- 12 yr), 60% affected by limited SSc and 80% by severe
DU (average nDU = 3) were included. Twenty percent of patients
had longer SSc history and more severe DU. All patients received
home treatments; 55% also received outpatient care; 85%
received on average 3.7 cycles of prostanoids (iloprost or alpros-
tadil) in the DH setting, 15% were also hospitalised. DU com-
plications, mostly superinfections, occurred in 85% of patients.
80% of patients healed. In the NHS perspective, cost of DU is on
average €23,730 per patient/year, 71.8% due to DH treatments
(including prostanoids) and 23.7% to management of complica-
tions; cost per patient varies from €20,533 (no complications,
average nDU = 1) to €24,295 (with complications, average
nDU = 4); main cost driver is the number of DH accesses. Out-
of-pocket expenditure is lower for patients with complications
(€360 vs. €900/year) as cost of complications is mainly borne by
the NHS. Cost/patient/year is on average €26,756 in the societal
perspective (€27,309 and €23,619 with/without complications);
indirect costs increase when complications occur. CONCLU-
SION: Despite the small sample, DU economic burden is relevant
because of DH treatments and complications’ management. In
absence of complications, cost of management shifts to patients’
charge.
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OBJECTIVES: Crohn’s disease (CD) is a potentially expensive
disease as it is a chronic, not curable condition with high hospi-
talisation rates. The objective of the study was to estimate the
health care resource use and epidemiology in a large UK popu-
lation. METHODS: This was a retrospective study using NHS
inpatient data (HES data) from 2001 over a period of 5 years
representing England (population in 2001 49,140,000). To
compare these results data from the region of Cardiff, Wales, UK
(population in 2003 approximately 434,000) was used. This data
contains inpatient, outpatient, biochemistry and mortality data
over a period of at least 12 years that has undergone record
linkage. Patients included were those with a diagnosis of CD
(ICD-10 K50*) as cause of admission. Number, type and method
of admission, incidence and survival were analysed. HRGs were
used to calculate inpatient costs. RESULTS: A total of 18,573
patients were identiﬁed in the NHS data [644 Cardiff data], of
whom 7,666 (41.3%) [250 (38.8%) Cardiff data] were male. The
average incidence was 14 per 100,000 per year. Mean length of
stay for primary index admissions was 9.2 (SD 14.7) days and
mean costs 2304 (SD 2778). Re-admission rates (primary or
secondary ICD code) in the year after index admission were 1.36
(SD 3.26) and disease related 0.83 (SD 2.34) per patient; average
length of stay per admission were 6.5 (SD 14.6), average costs
1776 (SD 2692). Surgery rate in the year after index admis-
sion was 0.16 (SD 0.46); average length of stay 12.5 (SD 22.1),
average costs per surgery 4048 (SD 4158). The rates declined
over the follow-up years. Hospital days, costs and rates approxi-
mately matched the Cardiff data, but were slightly higher. CON-
CLUSION: This study provides epidemiological and resource use
information on patients with CD. It conﬁrms the high resource
use and gives insight into determinants.
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OBJECTIVES: Ulcerative colitis (UC) is a potentially expensive
disease since it is a chronic condition with high hospitalisation
rates. The objective of the study was to estimate the health
care resource use and epidemiology in a large UK population.
METHODS: This was a retrospective study using NHS inpatient
data (HES data) from 2001 over a period of 5 years representing
England (population in 2001 49,140,000). To compare these
results data from the region of Cardiff, Wales, UK (population in
2003 approximately 434,000) was used. This data contains inpa-
tient, outpatient, biochemistry and mortality data over a period
of at least 12 years that has undergone record linkage. Patients
included were those with a diagnosis of UC (ICD-10 K51*) as
cause of admission. Number, type and method of admission,
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